Pollens are made up of tiny particles released by trees, plants and
grasses during spring and summer as part of their reproductive cycle.
Pollen owing to its fine particles can be easily inhaled by humans
and animals which can cause significant irritation and inflammation
to some people. Allergic rhinitis or hay fever is among the most
common form of allergy caused by grass pollen. According to a study
conducted by American College of Allergy, Asthma & Immunology in
2010 reported that about 16.9 million adults and 6.7 million children
were diagnosed with hay fever and its prevalence is increasing by
approximately 30% in adults and 40% in children. The Charity Allergy
U.K estimated that about 18 million people found to be affected with
grass pollen allergy and is more common among children and teenagers.
Symptoms of grass pollen include frequent sneezing, running or
blocked nose, itchy eyes and throat. In some instances it can also
lead to loss of senses to smell, facial pain, sweating and severe
headache. People suffering from asthma face even a worse symptom
which include tight chest, shortness of breath, coughing and
wheezing. The United States Food and Drug Administration in 2014
estimated around 30 million people in the United States and 500
million globally suffer from one or other form of hay fever symptoms.
There are about 1,200 species of grass grown in North America wherein
only a small percentage of them cause allergies. Some of the
prominent species include Bermuda grass, Johnson grass, Kentucky
bluegrass, Orchard grass, Redtop grass, Sweet vernal grass and
Timothy grass. The standard treatment for grass allergies includes
oral steroids, antihistamines, beta agonist and immunotherapy
treatment by injections. In May 2013, Health Canada approved a drug
Oralair which can treat allergies from five different pollen grasses.
Pills based immune therapy has seen significant demand and popularity
in past 2-3 years owing to its characteristics such as convenience
and painless option than weekly or monthly allergy shots. Merck &
Co. in April 2014 received FDA approval for its grass pollen allergy
drug Grastek. Merck estimates a potential U.S. market of nearly 3
million patients that will eventually be worth USD 1 billion of
annual sales. Possible side effects of Grastek include dizziness,
severe stomach pain, troubled swallowing and irregular heartbeat.
Obtain the Future Insights of Grass Pollen Allergy at:
http://bit.ly/2fgqUTL
Drivers to the growth of the market include exponential rise in
number of patient suffering from pollen based allergies and more
precisely hay fever. Moreover occupational exposure and growing
number of patients especially children are another major contributors
for escalating the global grass pollen allergy market. Lack of
permanent cure to grass pollen allergy disease and home based
diagnosis are few restraints to the growth of the global grass pollen
allergy market. Geographically market for grass pollen allergy is
majorly dominated by European and the North America market pertaining
to research funding, government interventions and frequent product
approvals. Moreover the Asia Pacific and Rest of the World market are
among the fastest growing regions. According to an independent study
conducted by Katelaris C., et. al. on Patterns of Allergic Rhinitis
and Asthma in Adults and Children in Asia Pacific: Findings From the
Allergies in Asia Pacific Survey. Allegergies in Asia-Pacific: A
landmark survey of nasal allergy suffers reported that about 48% of
Asia Pacific has been diagnosed with nasal allergies. About two out
of five of the diagnosed people were reported to be diagnosed with
allergic rhinitis.
Some of the prominent pipelined drugs in the market include MK-7243,
Pollinex Quattro Grass, Avanz Phleum Pratense, gpASIT + TM,
Grass-SPIRE, BM-32 and AllerG. Key players in the market include
Allergy Therapeutics plc, Allergopharma Joachim Ganzer KG, Circassia
Holdings Ltd., Laboratorios LETI S.L., Anergis SA, Biomay AG and
others
No comments:
Post a Comment